Tumor hypoxia drives metastatic progression, drug resistance, and posttreatment relapses, but how cancer cells adapt and evolve in response to hypoxic stress is not well understood. In this study, we address this question with the discovery that the receptor tyrosine kinase RON translocates into the nucleus of hypoxic cancer cells. In response to hypoxia, nuclear RON interacts with the hypoxia-inducible factor HIF-1a in a manner that relies on RON tyrosine kinase activity, binding to the c-JUN promoter and activating it. Mechanistic investigations revealed unexpectedly that nuclear RON played a more important role in activation of the c-JUN promoter than HIF-1a, leading to increased cell proliferation, survival adaptation, in vitro migration, and tumorigenicity under hypoxic conditions. Taken together, our results pointed to a novel function for RON as a transcriptional regulator that promotes the survival of cancer cells subjected to hypoxia. These results suggest novel implications for the use of small-molecule inhibitors or monoclonal antibodies targeting the RON kinase in the prevention or treatment of advanced cancer. Cancer Res; 74(16);
Introduction
Normal cellular responses to stress, which come from external and internal environments, are important barriers to carcinogenesis (1) . In the progression of carcinogenesis, cancer cells must develop a stress tolerance machinery to survive under harsh conditions (2) (3) (4) . Cells that have abrogated apoptotic or senescent pathways may show unimpeded growth despite signals that indicate activation of cellular stress (5) . Therefore, cancer cells have acquired the capability of selfsufficiency for growth signals in response to rigorous stresses, such as nutrient starvation, hypoxia, and pH change in microenvironments (6) .
Hypoxia is widespread in solid tumors when cancer cells outgrow the existing vasculature (7, 8) . It is well known that oxygen limitation is central in controlling neovascularization, glucose metabolism, cell survival, and tumor metastasis (9) . The adaptation of cancer cells to hypoxia also makes them resistant to cancer therapies (10) . Currently, several mechanisms have been proposed to explain hypoxia-associated cancer progression (11) . Hypoxia-inducible factor 1-alpha (HIF-1a) is the crucial transcription factor that mediates cellular responses to hypoxia (12) . In addition, epidermal growth factor (EGF) induces HIF-1a in the absence of low oxygen tension (13) , with a higher extent of EGF receptor (EGFR) activation during hypoxia (14) . These findings support a link between growth factor signaling and HIF-1a activity.
Receptor tyrosine kinases (RTK) are crucial in many cellregulatory processes. RTK-mediated signaling is a key mechanism by which most extracellular information is conveyed to the nucleus in response to stress (15) . Perturbations of RTK signaling by aberrant receptor activation or genetic alteration induce deregulated kinase activity and malignant transformation (16) . Thus, RTKs and their downstream signaling effector proteins are important targets of cancer therapy (17) . Despite this, accumulating data indicate that nuclear translocalized RTKs directly contribute to gene regulation when they are stimulated by their cognate ligands (18) , or modulate DNA repair in response to cisplatin and ionizing radiation treatment (19) . Thus, RTKs directly translocate into nuclei and act as transcriptional regulators in response to microenvironmental stress.
RON (Recepteur d'Origine Nantais), also known as MST1R (macrophage stimulating 1 receptor), belongs to the c-Met RTK superfamily (20) . The prognostic relevance of RON overexpression has been reported in a variety of cancers, including breast, colon, liver, pancreas, prostate, kidney, pancreas, and urinary bladder cancer (21, 22) . Hence, RON and its interaction 1 proteins are promising anticancer targets. We recently reported that nuclear translocation of RON may occur in a complex with EGFR in serum-starved cancer cells to activate the transcriptional machinery crucial for survival (23) . In addition, pretreatment with diphenyleneiodonium (DPI), a nicotinamide adenine dinucleotide phosphate NAD(P)H oxidase inhibitor, abrogated the nuclear trafficking, suggesting the involvement of NDA(P)H oxidase in the nuclear translocation of RON during serum starvation. Because reactive oxygen species (ROS) are produced by NAD(P)H oxidase during hypoxic stress (24) (25) (26) , we hypothesize that nuclear translocation of RON may occur as an adaptive mechanism for cancer cells in response to hypoxia.
In this study, we provide evidence that nuclear translocation of RON occurs after hypoxia, and that it is independent of EGFR. More interestingly, nuclear RON interacts with HIF-1a during hypoxic stress, and the tyrosine kinase activity of RON is required for this interaction. The RON-HIF-1a complex binds Figure 1 . The kinetics of the subcellular distribution of RON under hypoxia. A, confocal microscopy was used to examine the subcellular distribution of RON in TSGH8301 cells after exposure to hypoxia for different periods. B, the same experiment was performed under normoxia. HIF-1a was stained as a hypoxia marker. Nuclei were stained with DAPI. Scale bars, 10 mm. C, relative intensity in the nuclear (Nu) and nonnuclear (Non-Nu) fractions under hypoxia was quantified and expressed as a histogram. D, Western blot analysis was performed on subcellular compartments of hypoxic cells. The b-tubulin and Lamin B were used as the cytosolic and nuclear markers, respectively. E, the growth kinetics in response to normoxia or hypoxia was measured using an MTT assay. The results (means AE SD) were derived from three independent experiments. ÃÃÃ , P < 0.001, by two-way ANOVA. The interaction of nuclear RON with HIF-1a under hypoxia. A, pSUPER-HIF-1a-si plasmid was transiently transfected into TSGH8301 cells to knockdown HIF-1a expression and exposed to hypoxia for different periods. DAPI was used as a nuclear marker. Scale bars, 10 mm. Arrows, nuclear RON occurred in HIF-1a-knockdown cells after hypoxia. Arrowheads, both nuclear RON and HIF-1a were colocalized in the nuclei. (Continued on the following page.)
to the c-JUN promoter, synergistically activates the expression of the c-JUN gene, and stimulates cell proliferation, survival, and migration in vitro, and tumorigenicity in vivo.
Materials and Methods
Cell culture and oxygen deprivation The human bladder cancer cell line J82 and embryonic kidney HEK293 cells were obtained from the American Type Culture Collection, and authenticated by short tandem repeat (STR) PCR profiling in 2014 (Genomic Center, National Cheng Kung University, Taiwan). The human grade 2 urothelial carcinoma TSGH8301 cell line was purchased from Bioresource Collection and Research Center and authenticated in 2014 by STR PCR. All cell lines were maintained in DMEM (Invitrogen) supplemented with 10% FBS (Hyclone) and antibiotic/antimycotic solution (Caisson Laboratories). Cells were cultured at 37 C in a humidified atmosphere of 5% CO 2 . The day before experiments, cells were seeded in 6-or 10-cm dishes overnight, refreshed the medium next day, and then placed in a hypoxia chamber (NexBiOxy) filled with 95% N 2 and 5% CO 2 to maintain O 2 at 1% for different periods. The hypoxic equipment was plated within a 37 C humidified incubator (Forma).
Transient and stable knockdown transfection experiments
For transient transfection, RON shRNA (pSuper-RONi) was prepared in an RNAi system (pSuper; Oligoengine) using the target sequence 5 0 -ACT ACT TGC TGT ATG TGT CCA-3 0 . The HIF-1a shRNA (pSUPER-HIF-1a-Si) was provided by Dr. KouJuey Wu (National Yang-Ming University, Taipei, Taiwan). Stable knockdown strategies were designed using the BLOCK-iT Pol II miR RNAi Expression Kit (Invitrogen). The details of the target sequences are provided in the Supplementary Materials and Methods. The stable knockdown cell lines were selected with blasticidin. The positive colonies were screened using RON or EGFR Western blotting to confirm the knockdown efficiency.
Immunohistochemical staining, immunofluorescence staining, and confocal microscopy Immunohistochemical (IHC) staining, immunofluorescent staining, and confocal microscopy were done as previously described (23) . Antibody for human RON (C-20; Santa Cruz Biotechnology) at 1:200 dilution or HIF-1a (BD Transduction Laboratories) at 1:400 dilution was incubated overnight at 4 C. Then, cells were incubated with either Alexa Fluor488 (mouse) or Alexa Fluor594 (rabbit)-conjugated secondary antibody (Invitrogen) at room temperature for 1 hour. DAPI was used for nuclear staining. The image analysis was performed by a FV1000 confocal microscope (Olympus) using 60Â/1.4 NA oil objective lens (PLAPO). The images were adjusted using the Photoshop CS5 software (Adobe). The intensity of nuclear RON was measured by the ImageJ software. The primary antibody for IHC staining on tumor tissue included anti-RON b (Santa Cruz Biotechnology), HIF-1a (Abcam), CD31 (Dako), or nucleolin (Santa Cruz Biotechnology).
Cellular fractionation, Western blotting, and coimmunoprecipitation
Cellular fractionation was performed using Lamond's protocol (details at http://www.lamondlab.com/f7nucleolarpro-tocol.htm) with modification (Supplementary Materials and Methods). Primary antibodies used included RON (Santa Cruz Biotechnology), HIF-1a (Novus Biologicals), FLAG (SigmaAldrich), or HA (Covance; 1:1,000 dilution), and secondary antibodies were horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit antibody (Santa Cruz Biotechnology) at a 1:5,000 dilution. The membrane was exposed to a radiographic film and developed using chemiluminescent HRP substrate (Millipore).
Cloning of RON truncation mutants and c-JUN promoter deletion mutants
The functional domain deletion mutants of RON constructs were executed in two steps: first, the A fragment was amplified and ligated to p3xFLAG-CMV using EcoRI and BglII restriction sites. Second, the B fragment was amplified and ligated to p3xFLAG-CMV-A using BglII and XbaI restriction sites. For serial deletion constructs of c-JUN promoter, À1298/þ731, À876/þ731, À243/þ731, À156/þ731, and À34/þ731 were amplified using PCR with specific primers, and then inserted into the pGL3 basic vector by MluI and XhoI restriction sites (Supplementary Materials and Methods).
Statistical analysis
Data were analyzed using a paired two-tailed Student t test or two-way ANOVA, as appropriate.
Results

Subcellular distribution of RON in cancer cells under hypoxic stress
We showed that NAD(P)H oxidase-derived ROS are involved in the nuclear translocation of RON (23) . Because hypoxia upregulates the NAD(P)H oxidase, we examined whether hypoxia triggers nuclear translocation of RON in human cancer cells. Using TSGH8301 cancer cells harboring high level of endogenous RON ( Supplementary Fig. S1A ), subcellular distribution of RON was investigated in vitro in the presence of hypoxia (1% O 2 ) compared with normoxia (21% O 2 ). Confocal microscopy showed a time-dependent nuclear translocation of (Continued.) B and C, cells were transfected with pSUPER or pSUPER-HIF-1a-si and exposed to hypoxia for different periods. Western blotting was performed on co-IP using anti-RON (B) or anti-HIF-1a (C) antibody. The input samples were loaded at 5% of immunoprecipitate lysate. D, confocal microscopy showed that endogenous RON (red) was colocalized with HIF-1a (green) in the nuclei after 3 hours of hypoxia. Scale bars, 5 mm. D, bottom, percentage of cells showing colocalized RON and HIF-1a in the nuclei was estimated for 10 different fields. E, total lysate was immunoprecipitated with RON antibody and probed with HIF-1a or RON antibody. F, immunoprecipitation was performed on subcellular fractions of hypoxic cells using RON antibody and probed with indicated antibodies. G, TSGH8301 cells were treated with serum starvation, hypoxia, or both for 3 hours. Total lysate was immunoprecipitated with RON antibody and probed with HIF-1a or RON antibody. WCL, whole-cell lysate.
RON after hypoxia (Fig. 1A ) compared with normoxia (Fig. 1B) . The ratio of nuclear RON fluorescent intensity was higher 1 hour after hypoxia compared with normoxia, and >50% of RON signals were accumulated in the nuclei 24 hours after hypoxia (Fig. 1C) . The biochemical fractionation experiments showed a time-dependent nuclear translocation of RON after hypoxia (Fig. 1D) . Growth kinetics of TSGH8301 cells showed no significant difference within 24 hours (Fig. 1E) . Confocal microscopy also demonstrated nuclear translocation of RON in both hepatoma (Huh7) and colon cancer (SW480) cells after hypoxia ( Supplementary Fig. S1B and S1C), suggesting that hypoxia initiates the translocation of cell-surface RON receptors into the nuclei of human cancer cells.
Nuclear translocation of RON during hypoxia is independent of EGFR
Nuclear RON, in a complex with EGFR, is translocated to cell nuclei in response to serum starvation (23) . To examine whether EGFR is important for nuclear translocation of RON, subcellular distribution of both the RTKs was examined after RON or EGFR had been knocked down. TSGH8301 cells were established as negative control ( Fig. 2A) , and EGFR knockdown (TSGH8301/kdEGFR; Fig. 2B ) and RON knockdown (TSGH8301/kdRON; Fig. 2C ) were established as stable cells, respectively. Quantifying the fluorescent intensity showed a time-dependent increase of nuclear HIF-1a expression after hypoxia in negative control stable cells (90% of the total fluorescence accumulated in the nuclei 12 hours after hypoxia; Fig. 2D ), a time-dependent nuclear translocation of RON in EGFR-knockdown stable cells (60% of the total fluorescence accumulated in the nuclei 12 hours after hypoxia; Fig.  2E ), and, in contrast, a time-dependent increase of nuclear EGFR in RON-knockdown stable cells (about 50% of total EGFR fluorescence accumulated in the nuclei 12 hours after hypoxia; Fig. 2F ). Levels of RON and EGFR expression in stable knockdown cell lines were confirmed ( Fig. 2G and H) . These results support that EGFR and RON can be translocated into nuclei in response to hypoxia. Nuclear translocation of RON is independent of EGFR when cancer cells are exposed to hypoxia, and vice versa.
Nuclear translocation of RON during hypoxia does not require HIF-1a
To investigate the significance of HIF-1a for nuclear trafficking of RON, TSGH8301 cells were transiently transfected with pSUPER-HIF-1a-si, and then exposed to hypoxia for different periods. When HIF-1a was knocked down, confocal microscopy still showed RON in the nuclei after hypoxia for 3, 6, 12, and 24 hours (Fig. 3A, arrow) . This is in sharp contrast with nontransfected cells showing nuclear accumulation of HIF-1a that was colocalized with nuclear RON after hypoxia (Fig. 3A,  arrowheads) . These findings suggest that machinery involved in nuclear trafficking of RON in response to hypoxia does not require HIF-1a. More interestingly, a transient knockdown experiment unexpectedly demonstrated an association of nuclear RON with HIF-1a during hypoxia.
To confirm the association of nuclear RON with HIF-1a during hypoxia, TSGH8301 cells were transiently transfected with the control vector (pSuper) or pSuper-HIF-1a-si plasmid and then exposed to hypoxia. Western blotting of the co-IP using anti-RON (Fig. 3B) or anti-HIF-1a (Fig. 3C ) antibody demonstrated interaction of nuclear RON with HIF-1a after hypoxia for 3, 6, 12, or 24 hours after HIF-1a was knocked down. Taking together, nuclear RON is associated with HIF-1a in the hypoxic nuclei; however, molecular targets of the nuclear RON-HIF-1a complex require clarification.
Interaction of nuclear RON with HIF-1a in response to hypoxia
We showed that nuclear translocation of endogenous RON occurred 3 hours after hypoxia and is colocalized with HIF-1a (Fig. 3D) . Quantification confirmed a time-dependent increase of nuclear RON colocalized with HIF-1a within 24 hours of hypoxia (Fig. 3D, bottom) . This observation was supported by immunoblotting of hypoxic cells after co-IP using anti-RON antibody on total cell lysates ( Fig. 3E ) and subcellular fractions (Fig. 3F) . These experiments had been reconfirmed by two additional RON antibodies ( Supplementary Fig. S2 ). Further experiment revealed that hypoxia is more influential in driving nuclear translocation of RON and is independent of serum starvation (Fig. 3G) .
The interaction of HIF-1a with nuclear RON is dependent on tyrosine kinase domain
To identify the functional domains responsible for the interaction of nuclear RON with HIF-1a, deletion mutants for five functional domains of RON were generated ( Fig. 4A and Supplementary Fig. S3 ). The molecular weight of different RON mutants was confirmed by Western blot analysis (Fig. 4B) . Domain mapping was performed by cotransfecting domain deletion mutants of p3xFlag-RON and pHA-HIF-1a into HEK293 and then incubating in hypoxia for 24 hours. The IP/Western blot experiment showed that truncation of the tyrosine kinase domain (RONDTyrK) abolishes the interaction of RON with HIF-1a after hypoxia (Fig. 4C) . In contrast, the oxygen-dependent degradation (ODD) domain of HIF-1a was not involved in the interaction with RON (Fig. 4D) .
J82 bladder cancer cells harboring low levels of RON were chosen for the examination of subcellular distribution of domain mutants of RON and HIF-1a (Supplementary Fig.  S1A ). HIF-1a was shown to interact with RONDTM and RONFL in a hypoxia-dependent manner, but not with RONDTyrK ( Fig.  4E and F) . To examine the significance of a nuclear localization signal (NLS) on the interaction of the tyrosine kinase domain of RON with HIF-1a, TyrK, and TyrK-carrying NLS [TyrK(N)] were also constructed (Fig. 4A) . As shown in Fig. 4G and H, the interaction of HIF-1a with the tyrosine kinase domain of RON during hypoxia was noticeable in the presence of NLS.
Cooperation of nuclear RON and HIF-1a in the activation of c-JUN promoter under hypoxia
c-JUN was shown as a stress-responsive gene targeted by nuclear RON (23) . We demonstrated a dose-dependent activation of c-JUN promoter (full-length, À1780/þ731-c-Jun-Luc) by RON or HIF-1a ( Supplementary Fig. S4A and S4B), with a potential synergistic effect ( Supplementary Fig. S4C and S4D ). Interestingly, RONDTM seems to have a higher affinity with HIF-1a in the activation of the c-JUN promoter ( Supplementary  Fig. S4D ). These observations were confirmed in HEK293 stable cell lines that overexpressed control vector, RONDTM, RONDTyrK, or RONFL under hypoxia. c-JUN promoter activity was significantly higher in RONDTM and RONFL stable cells than in the vector and RONDTyrK cells (Fig. 5A) , supporting the involvement of nuclear RON in the activation of the c-JUN promoter during hypoxia.
To explore the mechanism of nuclear RON in the transcriptional activation of c-JUN, sequence of the c-JUN promoter was analyzed using the MacVector software to identify the potential binding sites for RON (Supplementary Fig. S5A ). Serial deletion mutants of c-JUN promoter constructs were generated ( Supplementary Fig. S5B ) and transfected into TSGH8301 cells for a luciferase reporter assay (Fig. 5B) . Our results showed that luciferase activities of full-length and deletion mutants À1298, À876, and À243 were significantly higher under hypoxia than under normoxia (Fig. 5B) . However, we found no difference in luciferase activity when promoter deletion was further extended to À156 and À34, indicating that the promoter region from À243 to À156 contains positive regulatory elements of hypoxia. These results demonstrated that the D box of the c-JUN promoter is the putative binding site for nuclear RON.
To identify the impact on c-JUN promoter transactivation, knockdown of RON in TSGH8301 cells showed a 25% decrease in À243/þ731-c-Jun-Luc promoter activity, and knockdown of both RON and HIF-1a showed a 50% decrease (Fig. 5C ). In contrast, no significant difference in promoter activity was observed in the HIF-1a knockdown experiments. The conspicuous inhibition of c-JUN promoter activity in cells transfected with RON and RON-HIF-1a double-knockdown cells implies that both RON and HIF-1a form a complex that binds to the c-JUN promoter.
To examine the importance of the D region's involvement in modulating the c-JUN promoter, mutant D box was replaced with HindIII and EcoRI cleavage nucleotide sequences in À243/ þ731-c-Jun-Luc (À243/þ731-mutD-c-Jun-Luc). Promoter activity of À243/þ731-mutD-c-Jun-Luc was inhibited compared with À876/þ731-c-Jun-Luc or À243/þ731-c-Jun-Luc (Fig. 5D) . Experiments of putative binding site mutants and knocking down RON and/or HIF-1a support that a cis-acting element of the D box is critical for the binding of nuclear RON and the RON-HIF-1a complex with activation of the c-JUN promoter during hypoxia.
ChIP was used to examine whether box D of the c-JUN promoter is a cis-acting element for nuclear RON-HIF-1a complex binding during hypoxia (Fig. 5E, top) . We demonstrated a hypoxia-dependent complex of nuclear RON-HIF-1a and binding to the c-JUN promoter (Fig. 5E-I ). In addition, RON knockdown abolishes the association of the RON-HIF-1a complex with the c-JUN promoter during hypoxia (Fig. 5E-II) . To our surprise, nuclear RON bound to the c-JUN promoter even though HIF-1a had been knocked down (Fig. 5E-III) . These data imply that nuclear RON is more important than HIF-1a in the transactivation of the c-JUN promoter during hypoxia. Expression of c-JUN protein was reduced when RON or both HIF-1a and RON were knocked down, with comparable reduction of À243/þ731-c-Jun-Luc promoter activity (Fig. 5G and C) . The potential effect of RON-regulated HIF-1a stability was examined using cycloheximide and showed prolonged stabilization of HIF-1a protein expression in cells overexpressing RONDTM or RONFL (Fig. 5F ). In addition, the dominant-negative mutant RON (K1114M) abolished the interaction with HIF-1a and downregulated the c-JUN promoter activity, supporting that tyrosine kinase activity of RON is required for its biologic functions in the nuclei (Supplementary Fig. S6 ).
Taken together, nuclear RON is the major transcriptional regulator of the c-JUN promoter region from À243 to À156 during hypoxia. In addition, c-JUN bound by the RON-HIF-1a complex was transcriptionally activated through the region À222/À210 upstream of the c-JUN promoter from the transcription start site.
Biologic effects of nuclear RON during hypoxia
The growth rate of RON knockdown stable cells (TSGH8301/ kdRON) under hypoxia was suppressed compared with vector control (TSGH8301/kdVector; Fig. 6A ). The clonogenic assay showed that RON knockdown significantly inhibited the survival of hypoxic cells compared with normoxic cells (Fig. 6B  and C) . These results support an essential role for RON in cell survival under normoxia; RON expression may confer a survival advantage to cancer cells under hypoxic stress.
To elucidate the biologic effects of nuclear RON under hypoxia, stable cell lines with RON-overexpressing mutants were generated in J82 cells. MTT assays showed a significantly higher growth rates in the RONFL and RONDTM cell lines than in the vector control and RONDTyrK cell lines (Fig. 6D) . The hypoxic adaption was also supported by a clonogenic assay (Fig. 6E and F) . Both RONDTM and RONFL cell lines had a higher growth rate than the vector control cell line (P < 0.001). The RONFL cell line showed a survival advantage compared with the RONDTM cell line at 24 and 48 hours only (P < 0.01).
The Transwell assay showed a higher migration rate for both RONFL and RONDTM stable cell lines than for vector control and RONDTyrK stable cell lines under hypoxia ( Fig. 6G and H) . The NOD/SCID mice experiments confirmed that both Figure 6 . The biologic functions of nuclear RON during hypoxia. A, the growth curve of TSGH8301 cells with knockdown control (TSGH8301/kdVector) or RONRONDTM and RONFL were more tumorigenic than vector control or RONDTyrK (Fig. 7A) . In addition, tumors developed in mice injected with RONFL cells were significantly larger after 8 and 9 weeks (P < 0.01 and P < 0.001, respectively) than those injected with RONDTM cells. Nuclear expression of RON was demonstrated by IHC in xenografts stably expressing RONDTM (Fig. 7B) . Nevertheless, RONDTM stable cells were active at inducing cell growth, survival adaptation, migration in vitro, and tumorigenic in vivo than vector control or RONDTyrK stable cells. These biologic effects could be ascribed to the nuclear translocation of RON mutants, and their bonding to the c-JUN promoter was confirmed by biochemical fractionation and ChIP-PCR ( Supplementary Fig. S7A and B) in J82 stable cell lines.
Implication in bladder cancer patients
Expression of RON and HIF-1a was examined in a cohort of 16 pairs of human bladder cancer and adjacent nontumor tissue. Western blotting demonstrated overexpression of RON and HIF-1a in 62.5% (10 of 16) and 31.25% (5 of 16) of bladder cancer, respectively (Fig. 7C) . The topographic distribution of RON and HIF-1a was investigated by IHC. We showed that both HIF-1a and RON were localized in the nuclei of cancer cells ( Fig. 7D and Supplementary Fig. S8 ). Nuclear expression of RON was counted in relation to basement membrane (representative results shown in Fig. 7E) , and a distance of 70 mm was chosen as cutoff (11, 27) . Tumor cells remote from basement membrane have a significantly higher incidence of nuclear RON expression (P ¼ 0.008 by a paired t test; Fig. 7F ).
Discussion
To our knowledge, this is the first report that shows the transcriptional activation of c-JUN by nuclear translocation of RTKs in hypoxic human cancer cells. Our finding reinforces the hypothesis that membranous RON receptor directly translocates into the nuclei of cancer cells in response to alterations of the extracellular environment (Fig. 7G ). We demonstrated that nuclear translocation of RON in human cancer cells occurred 1 hour after hypoxia, with maximum reaching at 12 hours. The hypoxia-driven nuclear import of RON is independent of EGFR. However, this hypoxia model is different from our earlier serum starvation model in which ligand-independent nuclear translocation of RON occurs 3 hours after starvation and is associated with EGFR (23) .
It is well established that hypoxic microenvironment in a solid tumor contributes to aggressive progression and poor prognosis (28, 29) . The regulation of target genes by the nuclear HIF-1a-HIF-1b complex in a hypoxic environment is critical for cellular adaption to hypoxia (7) . Our transient transfection experiment demonstrated that nuclear translocation of RON after hypoxia remained unaffected even though HIF-1a was knocked down, suggesting a HIF-1a-independent regulatory mechanism. This contradicts an earlier finding (30), which reported the transcriptional activation of the RON promoter by HIF-1a during normoxia in human breast cancer cells that expressed high levels of endogenous HIF-1a. RON was not upregulated under normoxia in TSGH8301 bladder cancer cells with undetectable endogenous HIF-1a. In contrast, the interaction of the RON receptor with HIF-1a, rather than transactivation by HIF-1a, in the activation of the c-JUN promoter activity was substantiated by confocal microscopy, co-IP, biochemical subcellular fractionation experiments, and a promoter luciferase reporter assay. Consistent with our observations, the interaction of the Notch3 receptor with HIF-1a and von Hippel-Lindau protein in breast cancer cells was reported to regulate the expression of carbonic anhydrase 9 (31), one of the hypoxia-responsive genes (32) . Taken together, these findings highlight a novel adaptive machinery of cancer cells in response to hypoxic stress, in which membrane proteins migrate directly to the nucleus and act as a transcriptional regulator.
The importance of tyrosine kinase for the interaction of nuclear RON with HIF-1a during hypoxia is supported by functional domain mapping using the RONDTyrK deletion mutant and dominant-negative mutant RON (K1114M) experiments. Considering the current scenario of nuclear translocation of EGFR (18, 19, (33) (34) (35) , our finding coincides with EGFR that tyrosine kinase activity is required for nuclear EGFRinduced cyclin D1 transcription (18) . Thus, tyrosine kinase is important not only for the interaction of nuclear RTKs with other associated proteins, but it is also critical for transactivating their target genes.
We provide evidence that the RON-HIF-1a complex binds to the c-JUN promoter and synergistically activates the expression of the c-JUN gene in response to hypoxia. In addition to HIF-1a, the significance of nuclear RON as a transcriptional regulator during hypoxia was confirmed in RONDTM-and RONDTyrK-deletion mutant stable cell lines. This alternative signaling activation mechanism of RON is analogous to nuclear EGFR in the regulation of B-Myb, RNA helicase A, and STAT3 (18, 34, 36) . Recently, Reilly and colleagues (37) also reported an induction of c-JUN expression and related cell proliferation by the nuclear translocation of fibroblast growth factor receptor 1 in ATP-depleted cells.
In terms of biologic implications, stable RONDTM cells, representative of the nuclear translocation of RON, significantly induce the cell survival, proliferation, migration in vitro, and tumorigenicity in vivo, and the proliferation and migration of stable J82/RONDTyrK cells showed effects comparable with those of stable J82/control vector cells during hypoxia. We showed that RONDTyrK, although can be translocated to the nuclei, cannot bind to the c-JUN promoter ( Supplementary Fig. S5 ). Given that hypoxic adaptation of cancer cells is crucial for clonal evolution (7), mechanisms regulating the nuclear translocation of RON deserve further investigation to improve the efficacy of conventional therapy targeting RON receptor and/or its downstream signaling molecules.
Transcription factor AP-1 is activated by environmental stresses, such as heat shock, UV damage, or hypoxia with induced expression of c-JUN or fos (38, 39) . Transcriptional regulation of c-JUN and related hypoxic genes requires cooperation between c-JUN/AP-1 and HIF-1a (40, 41) . Using the TSGH8301 cell as a model, we hypothesize that the hypoxiaresponse core element is located at À243 to À156 upstream C) . Frozen tumor was chosen for RON staining, whereas paraffinembedded tissue was stained for CD31, nucleolin, and HIF-1a as an endothelial, hypoxic, and nuclear marker, respectively (Â200). E, the arrowheads (red) define the basement membrane and arrows (yellow) indicate the signals of nuclear RON in cancer cells. The asterisk ( Ã ) marks the region where the inset high-power image was taken. F, nuclear expression of RON was counted in relation to basement membrane, and a distance of 70 mm was chosen as cutoff. The measurement was carried out in six random fields and normalized to total cells counted (P ¼ 0.008 by a paired t test). G, hypothetical model for the nuclear translocation of RON in response to cellular stress. G and I, the conventional RON receptor-mediated signaling pathway. II, nuclear translocation of RON, in a complex with EGFR, in response to serum starvation (23) . III, nuclear RON interacts with HIF-1a as a complex and activates the c-JUN promoter activity, which increases the cell proliferation, migration, and tumorigenicity in vivo in response to hypoxia. from the transcription start site. This regulatory region is different from conventional À200 upstream from the transcription start site under normoxia (39, 42, 43) .
Further investigation revealed 25% and 50% suppressed functional activity of the À243/þ731 c-JUN promoter (À243/þ731-c-Jun-Luc) when RON or both RON and HIF1a, respectively, were knocked down. The ChIP experiment showed that binding of nuclear RON and HIF-1a to c-JUN promoter is hypoxia dependent. It is interesting that transcriptional activity of the c-JUN promoter was suppressed when the predicted RON binding site was mutated. We also showed that the RON-HIF-1a complex cannot bind to the c-JUN promoter during hypoxia when RON is knocked down; however, RON can bind to the c-JUN promoter during hypoxia when HIF-1a is knocked down, suggesting that nuclear RON may be important for regulating c-JUN activity during hypoxia when HIF-1a is absent. The present investigation implies that RON may act as a "bench player" in the transcriptional regulation of c-JUN during hypoxia. Because c-JUN promoter activity was not suppressed when HIF-1a was transiently knocked down, we cannot exclude the possibility that HIF-1a may associate with other transcriptional factors in modulation of the c-JUN promoter during hypoxia.
In conclusion, we describe a novel adaptive response of cancer cells under hypoxic stress, in which RON is translocated into nuclei and functions as a transcriptional regulator. Nuclear RON can activate the c-JUN promoter in the absence of HIF1a. In addition, nuclear translocation of RON confers a survival advantage to hypoxic cancer cells in vitro and in vivo. A smallmolecule inhibitor of tyrosine kinase or monoclonal antibodies targeting RON kinase could be an anticancer strategy to repress the tumorigenesis of nuclear RON.
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